TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Techne Corp (TECH) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has shown some positive financial performance in terms of net income and EPS growth, the lack of strong positive catalysts, hedge fund selling, and mixed analyst ratings suggest a cautious approach. Additionally, the technical indicators and options data do not strongly support a bullish sentiment. Holding the stock or waiting for a better entry point may be more prudent.
The MACD histogram is positive at 0.749 and expanding, indicating bullish momentum. However, the RSI is at 77.618, which is in the neutral zone, and the moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 56.008), which could limit further upside in the short term.
Analysts from UBS, TD Cowen, and Citi maintain a Buy rating with price targets ranging from $79 to $80, indicating long-term potential.
Hedge funds are selling, with a significant increase in selling activity (5004.01%). Gross margin dropped by 1.43% YoY, and revenue declined slightly by 0.39% YoY. Evercore ISI recently lowered its price target to $54, citing modest market improvements but no significant near-term growth drivers.
In Q2 2026, revenue dropped slightly by 0.39% YoY to $295.88 million. However, net income increased by 8.93% YoY to $38.00 million, and EPS grew by 9.09% YoY to 0.24. Gross margin declined to 65.29%, down 1.43% YoY, reflecting some pressure on profitability.
Analyst ratings are mixed. While UBS, TD Cowen, and Citi have Buy ratings with price targets of $79-$80, Evercore ISI recently lowered its price target to $54 and maintains an In Line rating. Stifel and Baird maintain Hold and Neutral ratings, respectively, reflecting cautious sentiment in the near term.
